Eko Health developed an AI algorithm that, combined with noninvasive heart tests, may be able to accurately identify pulmonary hypertension.

Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...

Columnist Anna Jeter reflects on her mental health needs and various treatment approaches since being diagnosed with PH at ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against the ...

The following is a summary of “Development of the pulmonary fibrosis, pulmonary vascular resistance, six minute walk distance, B-type natriuretic peptide, age (PVD-B65) risk score for patients with ...

Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 millionReceived CE Mark for LungFit PH® in ...

Long-term exposure to PM2.5, PM10, NO2 and ozone (O3) air pollution is associated with more hospital admissions for lower respiratory tract infections in adults.

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the ...

Patients with chronic obstructive pulmonary disease, interstitial lung disease and pulmonary hypertension experience improved ...

Desiree Teubert and Kyle Geisler of New Auburn are in a situation no parent ever wants to face. They are waiting for a kidney ...

Eko Health has been advancing the use of artificial intelligence to help providers detect the early signs of disease, ...